Select Publications

Preprints

Wahlroos S; Portman N; Bonder C; Hjorth M; Wilkinson A; Hastings J; Croucher D; Febbraio M; Gallego-Ortega D; Lim E, 2022, Exercise-induced modulation of the immune microenvironment in pre-clinical breast cancer models., http://dx.doi.org/10.21203/rs.3.rs-1789675/v1

San Juan BP; Hediyeh-Zadeh S; Rangel L; Milioli HH; Rodriguez V; Bunkum A; Kohane FV; Purcell CA; Bhuva DD; Kurumlian A; Castillo L; Lim E; Gill AJ; Ganju V; Dear R; O’Toole S; Vargas AC; Hickey TE; Goldstein LD; Lock JG; Davis MJ; Chaffer CL, 2022, Targeting phenotypic plasticity prevents metastasis and the development of chemotherapy-resistant disease, http://dx.doi.org/10.1101/2022.03.21.22269988

Lim E; Boyle F; Okera M; Loi S; Goksu SS; Hal GV; Chapman SC; Gable J; Chen Y; Price G; Hossein A; Gainford C; Ezquerra MB, 2022, An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with Advanced Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-1440521/v1

Tilley W; Hickey T; Selth L; Chia KM; Milioli H; Laven-Law G; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell S; Stelloo S; Iggo R; Alexandrou S; Caldon C; Abdel-Fatah T; Ellis I; Zwart W; Palmieri C; Sartorius C; Swarbrick A; Lim E; Carroll J, 2020, The Androgen Receptor is a Tumour Suppressor in Estrogen Receptor Positive Breast Cancer, http://dx.doi.org/10.21203/rs.3.rs-62718/v1

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v2

Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O’Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A, 2020, Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer, http://dx.doi.org/10.21203/rs.3.rs-16182/v1

Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, http://dx.doi.org/10.1101/2020.01.29.911883

Cazet AS; Hui MN; Elsworth BL; Wu SZ; Roden D; Chan C-L; Skhinas JN; Collot R; Yang J; Harvey K; Johan MZ; Cooper C; Nair R; Herrmann D; McFarland A; Deng N-T; Ruiz-Borrego M; Rojo F; Trigo JM; Bezares S; Caballero R; Lim E; Timpson P; O’Toole S; Watkins DN; Cox TR; Samuel M; Martín M; Swarbrick A, 2017, Targeting stromal remodeling and cancer stem cell plasticity to overcome chemoresistance in triple negative breast cancer, http://dx.doi.org/10.1101/215954


Back to profile page